Clinical Trial Update: Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial reports that frequent dosing of CERA improves nutrition and inflammation in hemodialysis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Malnutrition

Drugs mentioned

• CERA (epoetin beta pegol)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Anemia, Inflammation | Phase 4 | Status: COMPLETED